Akari Therapeutics PLC 8-K Filing

Ticker: AKTX · Form: 8-K · Filed: Dec 8, 2025 · CIK: 1541157

Sentiment: neutral

Filing Stats: 561 words · 2 min read · ~2 pages · Grade level 12.1 · Accepted 2025-12-08 08:00:32

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Akari Therapeutics, Plc Date: December 8, 2025 By: /s/ Abizer Gaslightwala Name: Abizer Gaslightwala Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing